Macrocyclic serine protease inhibitor compounds for treating an HCV infection

摘要

Disclosed herein are macrocyclic serine protease inhibitor compounds of formula (I), pharmaceutical compositions comprising the compounds, and processes of preparation thereof, wherein the variables are as defined in the specification. These macrocyclic serine protease inhibitor compounds are suitable for treating or preventing an HCV infection. Also disclosed are medicament combinations comprising said macrocyclic serine protease inhibitor compound in combination with a second antiviral agent selected from the group consisting of an interferon, ribavirin, amantadine, an interleukin, a NS3 protease inhibitor, a cysteine protease inhibitor, a phenathrenequinone, a thiazolidine, a benzanilide, a helicase inhibitor, a polymerase inhibitor, a nucleotide analogue, a liotoxin, acerulenin, an antisense phosphorothioate oligodeoxynucleotide, an inhibitor of IRES-dependent translation, and a ribozyme.